Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Degarelix Acetate

FDA-approved product (powder, subcutaneous), marketed as Firmagon.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Degarelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Degarelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Degarelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Degarelix in Taiwanese Patients With Prostate Cancer

    NCT01220869 · start 2010-12

    Registered record
    Registry ID
    NCT01220869
    Conditions
    Prostate Cancer
    Interventions
    Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-10
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix
    PhasePhase 3
    Registry statusCompleted

  • A Degarelix Trial in Patients With Prostate Cancer

    NCT01242748 · start 2010-10

    Registered record
    Registry ID
    NCT01242748
    Conditions
    Prostate Cancer
    Interventions
    Degarelix; Goserelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-10
    Completion
    2012-01
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix; Goserelin acetate
    PhasePhase 3
    Registry statusTerminated

  • A Trial of Degarelix in Patients With Prostate Cancer

    NCT00946920 · start 2009-06

    Registered record
    Registry ID
    NCT00946920
    Conditions
    Prostate Cancer
    Interventions
    Degarelix; Goserelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-03
    Enrolment
    859

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix; Goserelin acetate
    PhasePhase 3
    Registry statusCompleted

  • Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

    NCT00117286 · start 2005-03

    Registered record
    Registry ID
    NCT00117286
    Conditions
    Prostate Cancer
    Interventions
    Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2005-03
    Completion
    2009-11
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

    NCT00215683 · start 2005-02

    Registered record
    Registry ID
    NCT00215683
    Conditions
    Prostate Cancer
    Interventions
    Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2009-11
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix
    PhasePhase 2 / Phase 3
    Registry statusCompleted